Log In
Print
BCIQ
Print
Print this Print this
 

Trastuzumab-based bispecific zybody

  Manage Alerts
Collapse Summary General Information
Company Zyngenia Inc.
DescriptionZybody targeting angiopoietin 2 (ANG2; ANGPT2) and epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Angiopoietin 2 (ANG2) (ANGPT2) ; Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today